Founder and CEO of US online social media and social networking service Facebook Mark Zuckerberg. Photo by KENZO TRIBOUILLARD/AFP via Getty Images/FILE)
Mark Zuckerberg and his wife Priscilla Chan have donated $25 million through their foundation to a philanthropic effort organized by Bill Gates to explore new coronavirus treatments.
The Gates Foundation donated $50 million last week to what it’s calling the “COVID-19 Therapeutics Accelerator.” The initiative brings together life sciences companies to collaborate on the development of new vaccines, diagnostics, and treatments for COVID-19.
“The Therapeutics Accelerator will enable researchers to quickly determine whether or not existing drugs have a potential benefit against COVID-19,” Chan and Zuckerberg said in a press release. “We hope these coordinated efforts will help stop the spread of COVID-19 as well as provide shared, reusable strategies to respond to future pandemics.”
The two donations are the largest from tech billionaires since the coronavirus outbreak. Wellcome and Mastercard are supporting the effort as well.
The goal of the initiative is to either develop a new drug or adapt an existing treatment that it could help distribute alongside partnering pharmaceutical companies.
The 15 companies participating in the project kicked off the effort by sharing their proprietary libraries of molecular compounds that have some history of being tested with COVID-19.
The lineup includes big names in biotech such as Johnson & Johnson, Merck, Pfizer, Sanofi, and Bristol-Myers Squibb.
Ford CFO John Lawler joined Cheddar News to talk about the auto giant's Q1 earnings report that beat on revenue and EPS. Despite the good numbers, Lawler spoke to challenges Ford had to navigate. "We also see the continued disruption to the supply chain impacting our production, and that hit us in the first quarter as well. So it kept us from having an even stronger quarter," he said. Lawler noted that chip shortages leading to the supply constraints should ease up throughout the year.
Tech giant Microsoft won a military contract for the production of its IVAS (integrated visual augmentation system) combat goggles, based on its HoloLens ARG tech, worth up to $21.9 billion over 10 years. However, the Pentagon is now saying that the device "has not yet demonstrated the capability to serve as a fighting goggle," and that the Army made mistakes in the program's initial stages by not clearly describing minimum performance standards. While testing continues, concerns have grown outside of the Defense Department to Congress and even within Microsoft itself. Cheddar's Ken Buffa takes a deeper look at the possible boondoggle.
U.S. stocks fell sharply to close Tuesday's session, with the Nasdaq dropping 3.95% and hitting a new one-year low. Frances Newton Stacy, Director of Strategy for Optimal Capital, joins Cheddar News to discuss her reaction to how markets closed the session, and to break down Q3 2022 earnings from Microsoft. "Netflix was sort of the big warning, and I think Big Tech was down today in anticipation of these earnings," she says.
With Netflix losing 200,000 subscribers in one quarter, and CNN+ shutting down just weeks after launch, the streaming industry is in a place of uncertainty. Hundreds of people who once thought they had steady jobs now face potential unemployment as streamers figure out how to navigate the constantly changing landscape. Greg Martin, co-founder of Rainmaker Securities, joined Cheddar's Opening Bell to discuss the state of streaming, its troubles, and how its impacting hundreds of workers.
With mask mandates lifted across various parts of the country, healthy indoor air quality in public spaces is more crucial than ever before. According to the CDC, proper ventilation, in addition to other preventative measures, is instrumental to preventing the rapid spread of covid-19 indoors. As the push for higher air quality ramps up, AtmosAir is providing a high-tech solution for cleaner, greener air indoors. Steve Levine, CEO, AtmosAir, joined Cheddar’s Opening Bell to discuss.
